PULMONX CORPORATION Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-03-12: Study NCT06332885; Company role Lead sponsor; Phase Observational; Status Recruiting.
- 2024-02-22: Study NCT06035120; Company role Lead sponsor; Phase Not applicable; Status Recruiting.
- 2021-08-01: Study NCT04801108; Company role Collaborator; Phase Not applicable; Status Recruiting.
- 2021-06-01: Study NCT04256408; Company role Collaborator; Phase Not applicable; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-03-12 | NCT06332885 Zephyr Valve Japan Post-Marketing Surveillance | Lead sponsor | Observational | Recruiting | Emphysema; COPD; Severe Emphysema | 140 | 2028-03-31 |
| 2024-02-22 | NCT06035120 An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | Lead sponsor | Not applicable | Recruiting | Emphysema, Pulmonary; Emphysema or COPD | 200 | 2028-03-31 |
| 2021-08-01 | NCT04801108 Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema | Collaborator Lead: Beth Israel Deaconess Medical Center | Not applicable | Recruiting | Emphysema or COPD | 20 | 2026-08-01 |
| 2021-06-01 | NCT04256408 Mind The Gap - Crossing Borders Study | Collaborator Lead: University Medical Center Groningen | Not applicable | Completed | Emphysema; COPD; Hyperinflation Lung | 3 | 2022-08-31 |
| 2021-01-04 | NCT04517916 Zephyr Etude Post-Inscription (French Registry) | Lead sponsor | Observational | Completed | Emphysema or COPD | 155 | 2026-01-28 |
| 2020-12-15 | NCT04559464 Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT) | Lead sponsor | Not applicable | Completed | Emphysema; COPD; Severe Emphysema | 102 | 2024-10-21 |
| 2020-06-04 | NCT04465461 Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion | Lead sponsor | Not applicable | Completed | Pulmonary Emphysema | 9 | 2024-03-05 |
| 2020-02-05 | NCT04161235 Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV | Lead sponsor | Observational | Completed | Pulmonary Emphysema | 2 | 2021-12-30 |
| 2019-11-25 | NCT04186546 Zephyr Valve Registry (ZEVR) | Lead sponsor | Observational | Active not recruiting | Emphysema | 150 | 2026-12-31 |
| 2016-11 | NCT02877459 Clinical Investigation of a Modified Staged Treatment Algorithm Using the AeriSeal System | Lead sponsor | Not applicable | Completed | Emphysema | 14 | 2018-08-10 |
| 2014-01-28 | NCT02022683 To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves | Lead sponsor | Not applicable | Completed | COPD; Heterogeneous Emphysema | 97 | 2018-09-27 |
| 2013-07 | NCT01796392 Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) | Lead sponsor | Not applicable | Completed Results posted | Emphysema | 190 | 2023-04 |
| 2012-01 | NCT01101958 A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) | Lead sponsor | Not applicable | Completed Results posted | Emphysema | 96 | 2013-03 |
| 2008-05 | NCT00684892 Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR) | Lead sponsor | Phase 1, Phase 2 | Completed | Heterogeneous Emphysema | 25 | 2008-11 |
| 2008-05 | NCT00684684 Safety and Feasibility Study of the Chartis System | Lead sponsor | Phase 1 | Completed | Bronchoscopy | 18 | 2008-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |